NCT07226258

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 Injectable for the Treatment of Knee Pain in Patients With Osteoarthritis of the Knee

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Saol Therapeutics Inc · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 for the Treatment of Knee Pain in Patients with Osteoarthritis of the Knee.

Detailed description

This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single treatment of SL1002 compared to placebo for the treatment of knee pain associated with mild to moderate osteoarthritis.

Conditions

• Osteoarthritis Knee Pain

Interventions

Type	Name	Description
DRUG	SL1002	SL1002 injectable solution
DRUG	Normal Saline	Normal Saline

Timeline

• Start date: 2025-11-07
• Primary completion: 2026-11-30
• Completion: 2027-02-28
• First posted: 2025-11-10
• Last updated: 2026-03-25

Locations

18 sites across 1 country: United States

Regulatory

• FDA-regulated drug study